Assessing the need for quality-adjusted cost–effectiveness studies of nanotechnological cancer therapies

Doxil® — The first FDA-approved nano-drug: Lessons learned

(2012) Yechezkel (Chezy) Barenholz   JOURNAL OF CONTROLLED RELEASE

Overcoming regulatory and economic challenges facing pharmacogenomics

(2012) Joshua P. Cohen   New Biotechnology

Pharmacogenetics and cost-effectiveness analysis: a two-way street

(2011) Kalipso Chalkidou et al.   DRUG DISCOVERY TODAY

Future of nanomedicine: obstacles and remedies

(2011) Rita Bosetti et al.   Nanomedicine

Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes

(2010) Ioannis S. Vizirianakis   Nanomedicine-Nanotechnology Biology and Medicine

Criteria for deciding cost-effectiveness for expensive new anti-cancer agents

(2009) Rajiv Sarin   Journal of Cancer Research and Therapeutics

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer

(2008) George Dranitsaris et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE